Core Viewpoint - The announcement details the stock option exercise plan of Xinjiang Baihua Village Pharmaceutical Group Co., Ltd., highlighting the completion of the third exercise period and the second reserved grant period, with a total of 253,760 shares exercised, representing 10.02% of the total exercisable stock options [2][10]. Summary by Sections Stock Option Exercise Details - From July 1, 2025, to July 31, 2025, a total of 253,760 shares were exercised, with cumulative exercises reaching 2,459,205 shares, accounting for 97.08% of the total exercisable stock options [2][10]. - The stock options will be listed for trading on the second trading day after the exercise date [2]. Decision-Making Process and Disclosure - The decision-making process involved several proposals regarding the stock option incentive plan, which were approved by the board and independent directors [3][4]. - The supervisory board did not receive any objections during the public notice period regarding the incentive plan [3]. Stock Option Cancellation - A total of 1,207,650 stock options were canceled due to non-fulfillment of exercise conditions, reducing the number of incentive recipients from 162 to 149 [5]. - The total number of unexercised stock options was adjusted from 12,100,000 to 10,892,350 after the cancellation [5]. Exercise Conditions and Results - The first exercise period conditions were deemed fulfilled, allowing 176 individuals to exercise a total of 3,937,175 stock options at a price of 4.98 yuan per share [6]. - The third exercise period and the second reserved grant period conditions were also confirmed as fulfilled, allowing 149 individuals to exercise a total of 2,533,245 stock options at the same price [7][8]. Financial Impact and Fundraising - The company raised 1,263,724.80 yuan from the exercise of 253,760 shares, with total funds raised from the stock option plan amounting to 46,878,134.40 yuan, used to supplement working capital [10]. - The total number of shares increased from 384,293,875 to 384,547,635, but this change did not significantly impact the company's financial status or operating results [10].

Core Points - The announcement details the results of the third vesting period of the 2021 Restricted Stock Incentive Plan for Guangdong Liyang Chip Testing Co., Ltd, with 573,441 shares set to be listed on July 11, 2025 [1][12] - The plan involves a total of 205 participants, with 2,389,445 shares granted, of which 573,441 shares are now vested [9][12] - The company has completed the necessary registration procedures for the shares, and the total share capital will increase from 202,434,834 to 203,008,275 shares [10][11] Summary by Sections Incentive Plan Overview - The board approved the 2021 Restricted Stock Incentive Plan on May 17, 2021, with independent directors confirming its benefits for the company's sustainable development [2][4] - The plan was publicly disclosed and approved by shareholders during a meeting on June 2, 2021 [3][4] Vesting Details - The third vesting period has a total of 573,441 shares, with 205 individuals eligible for the vesting [9][12] - The shares represent 24% of the total granted shares for the respective participants [9] Stock Listing and Flow - The shares will be listed for trading on July 11, 2025, and the company has outlined restrictions on the transfer of shares for directors and senior management [10][11] - The total share capital will increase to 203,008,275 shares following the vesting [10] Financial Impact - The company reported a net profit of -7.5845 million RMB for Q1 2025, with the basic earnings per share at -0.04 RMB; the new shares will dilute earnings based on the increased total share capital [11][12]

Core Viewpoint - The announcement details the results of the first vesting period of the 2023 restricted stock incentive plan for Shanghai Nanchip Semiconductor Technology Co., Ltd, including the number of shares to be listed and the stock's circulation date [1][10]. Summary by Sections Incentive Plan Overview - The stock listing type is for equity incentive shares, with a total of 245,168 shares to be listed for circulation on June 20, 2025 [1][10]. - The company has completed the share registration for the first vesting period of the incentive plan for both the second category of incentive objects and the reserved grants for the first category [1][11]. Decision-Making Process - The board of directors and independent directors have approved the relevant proposals regarding the incentive plan, and the supervisory board has verified the list of incentive objects [3][6]. Vesting Details - For the second category of incentive objects, 11 individuals were granted a total of 360,973 shares, with 90,243 shares (25%) becoming vested [8]. - For the first category of incentive objects, 15 individuals were granted a total of 619,699 shares, with 154,925 shares (25%) becoming vested [8]. Stock Source and Listing Arrangements - The vested shares are sourced from the company's directed issuance of A-share common stock to the incentive objects [8]. - The total number of individuals receiving vested shares is 26 [8]. Capital Changes - The total share capital of the company increased from 425,457,743 shares to 425,702,911 shares following the vesting of the restricted stock [10]. - The number of unrestricted circulating shares increased by 245,168 shares [10]. Financial Impact - The company reported a net profit of RMB 63,492,563.31 for Q1 2025, with basic earnings per share of RMB 0.15. The vesting of shares will slightly dilute the earnings per share but is not expected to have a significant impact on the financial results [11].